1	A novel UNC93B1 gain-of-function mutation leads to
2	TLR7 and TLR8 hyperactivation and systemic lupus erythematosus
3	
4	Xu Han ^{1,7} , Ruoran Wang ^{1,7} , Seza Ozen ^{2,7} , Qintao Wang ^{1,7} , Wei Dong ^{3,4} , Yi Zeng ¹ , Ouyuan Xu ⁵ ,
5	Seher Şener ² , Li Guo ⁶ , Ying Gu ⁴ , Huanming Yang ^{3,4} , Xiaomin Yu ^{1,*} , Panfeng Tao ^{1,*} , Qing
6	Zhou ^{1,5,*}
7	
8	1 Liangzhu Laboratory, Zhejiang University, and Department of Rheumatology, The Second
9	Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10	2 Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University Faculty
11	of Medicine, Ankara, Turkey
12	3 Hangzhou Institute of Medicine Chinese Academy of Sciences, Hangzhou, China
13	4 BGI, Shenzhen, China
14	5 Life Sciences Institute, Zhejiang University, Hangzhou, China
15	6 Department of Rheumatology Immunology & Allergy, Children's Hospital, National Clinical
16	Research Center for Child Health, Zhejiang University School of Medicine, China
17	7 These authors contributed equally to this work
18	* These authors jointly supervised this work: Qing Zhou, Panfeng Tao, Xiaomin Yu
19	e-mail: zhouqingnwu@gmail.com; taopanfeng1109@gmail.com; yuxiaomin78@gmail.com
20	
21	Abstract
22	Dysfunctions in nucleic acid-sensing Toll-like receptors (TLRs) disrupt nucleic acid tolerance,
23	leading to systemic lupus erythematosus (SLE). Here, we report a novel homozygous gain-of-
24	function p.R95L mutation in the TLR chaperone protein UNC93B1 in an SLE patient. Bulk and
25	single-cell transcriptional analysis of the patient's peripheral blood mononuclear cells (PBMCs)
26	revealed significantly elevated inflammation in T cells and myeloid cells due to enhanced
27	dendritic cells function. The UNC93B1 R95L mutation leads to hyperactivation of TLR7/8, but
28	not TLR3/9, upon stimulation with specific agonists <i>in vitro</i> . Transgenic Unc93b1 ^{R95L/R95L} mice
29	develop inflammatory and autoimmune phenotypes, and the upregulation of inflammatory NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

signaling differs among organs, with a specific contribution of malfunctioned T cells and B
cells. In human and mouse cell lines, the *UNC93B1* R95L mutation promotes TLR7/8 signaling
by enhancing its binding to ssRNA, without affecting TLR7/8 translocation. Overall, our results
elucidate the pathology of organs and the immunological profiles of immune cell populations
in the development of SLE caused by the *UNC93B1* R95L mutation through the TLR7/8 axis.

35

36 Introduction

37 Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibodies targeting nuclear antigens and affecting multiple organ systems (1). 38 Monogenic lupus refers to a group of diseases with lupus-like symptoms caused by mutations 39 in single genes. These genes mainly affect complement pathways, type I interferon (IFN) 40 signaling, nucleic acid sensing, RAS signaling pathways, and immune tolerance(2). Identifying 41 these pathogenic genes is crucial for improving SLE classification and treatment. Genetic 42 diagnosis enables personalized treatment, and understanding the mechanisms and effects of 43 these mutations provides insights into SLE and other autoimmune diseases, aiding in the 44 45 development of targeted therapies.

46

Toll-like receptors (TLRs) are critical for recognizing microbial molecules and initiating immune
responses. They consist of an extracellular domain for ligand recognition, a transmembrane
domain, and a Toll-interleukin 1 receptor (TIR) domain for signaling. Upon ligand binding, the
TIR domain dimerizes and recruits proteins to form the Myddosome complex, which activates
pathways such as NF-κB and type I IFN(3).

52

A subset of TLRs recognizes various forms of nucleic acids: TLR3 binds double-stranded RNA, TLR7 and TLR8 bind single-stranded RNA (ssRNA) fragments, and TLR9 binds CpG singlestranded DNA(4). TLR7, found in dendritic cells (DCs), monocytes, and B cells, recognizes ssRNA within endosomes(5, 6). Loss-of-function (LOF) mutations in *TLR7* cause immunodeficiency(7), while gain-of-function (GOF) mutations lead to abnormal activation of NF-κB and type I IFN pathways, resulting in SLE-like symptoms such as autoimmune

thrombocvtopenia, elevated autoantibodies, complement deficiencies, arthritis, migraines, 59 and kidney involvement(8-10). TLR8, expressed in myeloid DCs, monocytes, and 60 neutrophils(11), also recognizes ssRNA in endosomes. GOF mutations in TLR8 cause 61 immunodeficiency and inflammation(12). Patients show immunodeficiency symptoms like 62 abnormal B cell differentiation, neutropenia, and infections, alongside inflammatory symptoms 63 like arthritis, vasculitis, fever, T cell activation, increased cytokine production, and elevated 64 NF-kB signaling. TIr8 in mice is generally considered non-functional, and little is known about 65 its regulation and role in autoimmune diseases. 66

67

UNC93B1 is a chaperone protein crucial for transporting TLR3, TLR7, TLR8, and TLR9 from 68 the endoplasmic reticulum (ER) to endosomes where these receptors initiate signaling(13, 14). 69 Mice with homozygous Unc93b1^{H412R} mutation are more susceptible to pathogens due to 70 impaired binding of Unc93b1 to TLR3, TLR7, and TLR9, trapping them in the ER and blocking 71 signal transduction(15). Patients with UNC93B1 LOF mutations are prone to herpes simplex 72 encephalitis due to dysfunctional endosomal TLRs, with reduced responses of immune cells 73 74 to TLR agonists(16). Understanding the role of UNC93B1 in TLR regulation is critical for elucidating its involvement in autoimmune diseases like SLE. Recent structures have 75 76 identified potential key regions involved in UNC93B1-TLR7 interactions(17), but the significance of these residues in UNC93B1 and TLR7 function remains unexplored. 77

78

Here, we identify a patient with early-onset SLE carrying homozygous *UNC93B1* R95L mutation. Through a series of experiments in human and mouse model, we elucidate the pathology of organs and the immunological profiles of immune cell populations in the development of SLE caused by the *UNC93B1* R95L mutation through the TLR7/8 axis.

83

84 **Results**

85 A novel UNC93B1 pathogenic mutation in a patient with early-onset SLE

86 The proband is a female who presented with symptoms suggesting early-onset SLE. These 87 symptoms included fevers, fatigue, discoid and maculopapular rashes, and

photosensitivity (Figure 1A). Immunologic studies revealed positive anti-nuclear antibody 88 (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies exceeding 800 U/L, as well as 89 positive anti-Smith (anti-Sm) and anti-Ribonucleoprotein (anti-RNP) antibodies. The patient 90 had hypocomplementemia with reduced levels of C3 (0.33 g/L, normal range 0.8-1.6 g/L) and 91 C4 (0.05 g/L, normal range 0.15-0.4 g/L). C-reactive protein (CRP) level was normal, her 92 erythrocyte sedimentation rate (ESR) was elevated, ranging between 40-60 mm/hour (normal 93 range 1-10 mm/hour). Based on the 2019 EULAR/ACR criteria(18), she was diagnosed with 94 95 early-onset SLE. Currently she is on prednisolone at a dosage of 5 mg/day, hydroxychloroquine at 150 mg/day, and mycophenolate mofetil at 750 mg/day. 96

97

98 Whole-exome sequencing of the proband and her parents identified a homozygous mutation 99 in *UNC93B1*: NM_030930:c.284G>T, p.Arg95Leu (R95L) (**Figure 1, B and C**). Her healthy 100 parents were heterozygous carriers of this variant. The R95 residue is highly conserved across 101 species (**Figure 1D**). This mutation was not found as homozygous in public databases, 102 including gnomAD v4, Kaviar, and chinaMap. *In silico* modeling predicted that this mutation 103 impacts protein function, with a CADD score of 35 and a GERP score of 4.55, both indicating 104 a deleterious effect.

105

106 Activation of inflammatory signaling in the patient

We obtained serum samples from the patient and quantified cytokines using cytometric bead array (CBA) and enzyme-linked immunosorbent assay (ELISA). The analysis revealed markedly increased production of proinflammatory cytokines IL-6 and IFN- α , chemokine IP-10, and macrophage colony-stimulating factors (M-CSF) and Granulocyte-CSF (G-CSF) compared to healthy controls (**Figure 1, E and F**).

112

To examine the transcriptional differences between the patient and healthy controls, we performed bulk RNA sequencing on peripheral blood mononuclear cells (PBMCs) samples. Differential gene expression analysis showed that expression of inflammatory response genes was elevated in patient compared to healthy controls (**Supplemental Figure 1A**). Gene set

enrichment analysis (GSEA) showed that type I IFN and NF-KB signaling were top-ranked 117 among the upregulated pathways in the patient (Supplemental Figure 1B). The heightened 118 expression of genes in type I IFN and NF-kB pathways were also observed in patient (Figure 119 **1G, Supplemental Figure 1A)**. These results suggested specific effect of these two pathways 120 in the patient's inflammatory manifestation. The changes in the type I IFN pathway genes were 121 notably pronounced. Quantitative PCR (qPCR) confirmed increased transcription of type I IFN, 122 including IFNA2 and IFNB1, type I IFN-stimulated gene (ISG) IFI44, as well as IL6, which is 123 124 regulated by the NF-kB pathway, in the patient compared to healthy controls (Figure 1H). Many SLE patients exhibit elevated levels of type I IFN, which correlates with the secretion of 125 autoantibodies, disease severity, and heterogeneity (19). Thus, the abnormal activation of the 126 type I IFN signaling pathway may be a critical factor contributing to the patient's SLE. 127

128

To further identify specific cell populations and immunological pathways involved in the 129 patient's pathology, we analyzed the single-cell transcriptomes of PBMCs from the patient and 130 three healthy controls. Based on the integration and unsupervised clustering of single-cell 131 132 sequencing data, we identified 18 cell populations according to specific profiles of marker gene expression (Figure 1I, Supplementary Figure 1C). Compared to healthy controls, patient's 133 PBMCs showed elevated signal in NF-κB and type I IFN pathways (**Figure 1J**). Differential 134 expression analysis displayed a distinct expression pattern of key genes in NF-κB pathway, 135 such as RELA, TNFAIP3 in myeloid cells and T cells, and critical genes in type I IFN pathway, 136 including ISG15, IFI44L in most immune cells (Figure 1K). Among myeloid cells, plasmacytoid 137 DCs (pDCs) are the primary interferon-producing cells(20), whereas monocyte-derived DCs 138 (moDCs) and conventional DCs (mDCs) could activate T cells through antigen presentation(21, 139 140 22). Enrichment of IL-17 and type I IFN signaling in DCs and T cells implicated specific contributions of DCs subsets, pDCs, mDCs, and moDCs, to the patient's manifestation 141 through T cell activation and type I IFN production (Figure 1L, Supplemental Figure 1D). 142

143

144 These results demonstrated dysregulated inflammatory regulation in the patient, suggesting 145 that *UNC93B1* R95L mutation plays a driving role in the activation of immune cell responses.

146

147 UNC93B1 R95L mutation promotes inflammation through TLR7/TLR8 activation

Unrestrained intracellular TLR activation can lead to responses to self-nucleic acids and 148 autoimmunity(8). To investigate the effect of the UNC93B1 R95L mutation on intracellular 149 TLRs (TLR3, TLR7, TLR8, TLR9), we co-expressed wild-type UNC93B1, UNC93B1 R95L 150 mutant, and UNC93B1 H412R mutant (negative control) with different TLRs in HEK293T cells. 151 We measured the NF-kB reporter activity and/or the levels of IL-8 transcription following 152 153 stimulation with specific TLR agonists (TLR3: Poly(I:C); TLR7/TLR8: R848; TLR9: ODN2216). These assays revealed that the UNC93B1 R95L mutation enhanced the activation of TLR7, 154 TLR8, and TLR9, but not TLR3 (Figure 2, A-D). 155

156

In the human monocytic cell line THP-1, the UNC93B1 R95L mutant enhanced activation by 157 the TLR7/8 dual agonist R848 and the TLR8-specific agonist TLR8-506, while there was no 158 significant effect on TLR3 and TLR4, which are UNC93B1-independent (Figure 2E). In mouse 159 macrophage cell line RAW 264.7 (where TLR8 is non-functional), the UNC93B1 R95L mutant 160 161 increased TLR7 activation upon R848 stimulation, significantly elevating the transcription levels of NF-kB downstream genes such as *Tnf* and *ll1b* (Supplemental Figure 2A). 162 Intracellular cytokine staining of Tnf further confirmed that the UNC93B1 R95L mutant 163 enhanced TLR7 activation by various TLR7 agonists (Figure 2F). Both chloroquine, which 164 inhibits TLR activation by altering endosomal pH and inhibiting the ectodomain cleavage, and 165 M5049, a small molecule inhibitor of TLR7/8, effectively suppressed R95L-induced TLR7 166 167 activation and its downstream signaling (Figure 2G).

168

Bone marrow-derived dendritic cells (BMDCs) and macrophages (BMDMs) from the
homozygous *Unc93b1^{R95L}* mice showed enhanced activation of NF-κB and type I IFN
signalings in response to TLR7 ligands but not ligands of TLR3, TLR4, and TLR9 (Figure 2,
H and I, Supplemental Figure 2B). Interestingly, in BMDCs, the transcription levels of both
NF-κB and type I IFN-related genes were significantly upregulated, whereas in BMDMs, type
I IFN-related gene expression showed no significant changes.

175

Collectively, experiments across human cell lines, mouse cell lines, and primary isolated
mouse cells demonstrate that the *UNC93B1* R95L mutation confers a gain-of-function effect
with selectively enhanced TLR7/8 but not TLR3/9 activation, leading to downstream NF-κB
and type I IFN signaling dysregulation.

180

181 Mice with *Unc93b1^{R95L}* mutation develop systemic inflammation and autoimmune 182 pathology

To verify that the UNC93B1 R95L mutation drives autoimmune manifestation and abnormal 183 inflammatory signaling, we generated Unc93b1^{R95L/R95L} knock-in mice on a C57BL/6J 184 background using CRISPR/Cas9 technology (Figure 3A). We monitored mice body weight 185 and cutaneous manifestation weekly, and measured plasma anti-dsDNA antibody level 186 biweekly from postnatal day 21 until the phenotype stabilized. Over a 9-week period, no 187 significant difference in body weight was observed between mutant and control mice, 188 regardless of sex (Figure 3B). Tissue analysis revealed that *Unc*93b1^{R95L/R95L} mice exhibited 189 190 significant splenomegaly and slight hepatomegaly compared to controls, whereas Unc93b1^{+/R95L} mice showed no differences (Figure 3C, Supplemental Figure 3A). Elevated 191 levels of autoantibodies (including dsDNA, dsRNA, and ANA), C-reactive protein, and C3 were 192 observed in Unc93b1^{R95L/R95L} mice compared to Unc93b1^{+/+} controls, as measured by ELISA 193 (Figure 3D). Given the weaker phenotype observed in males, we focused subsequent 194 inflammation analysis on female mice. Plasma cytokines and chemokines analysis revealed 195 elevated levels of pro-inflammatory cytokines II-6 and II-1 β , as well as the chemokine Cxcl1, 196 in Unc93b1^{R95L/R95L} mice compared to Unc93b1^{+/+} controls (Figure 3E). These data indicate 197 that the Unc93b1^{R95L} mutation leads to autoimmune and inflammatory phenotypes in mice, 198 recapitulating the clinical symptoms of the patient. 199

200

To further investigate the pathological mechanisms underlying the autoimmune and inflammatory symptoms in $Unc93b1^{R95L/R95L}$ mice, we analyzed the pathological differences in the spleen, kidney, lung, liver, brain, quadriceps, and plasma, comparing $Unc93b1^{R95L/R95L}$

204 mice with littermate controls.

205

Histological examination using hematoxylin and eosin (H&E) staining revealed significantly 206 increased number of splenocytes and enlarged white pulp areas in the spleens of both 207 *Unc93b1*^{+/R95L} and *Unc93b1*^{R95L/R95L} mice, with indistinct boundaries between the white and 208 red pulp (Figure 3F). Periodic acid-Schiff (PAS) staining of kidneys showed significantly 209 increased glomerulus areas in both Unc93b1^{+/R95L} and Unc93b1^{R95L/R95L} mice, with 210 inflammatory cell infiltration in the renal interstitial area, particularly around renal tubules in 211 *Unc93b1*^{*R95L/R95L*} mice (**Figure 3G**). This was accompanied by glomerular damage 212 characterized by increased cell numbers, immune complex deposition, and expansion of 213 mesangial matrix (Supplemental Figure 3B). Lung tissue analysis showed reduced alveolar 214 spaces and thickened septa in both *Unc93b1*^{+/R95L} and *Unc93b1*^{R95L/R95L} mice, with pulmonary 215 congestion noted in Unc93b1^{R95L/R95L} mice. The liver of Unc93b1^{R95L/R95L} mice exhibited 216 prominent glycogen storage within hepatocytes and marked inflammatory cell infiltration 217 (Figure 3H). These observations were consistent with significant hypoglycemia in 218 *Unc*93*b*1^{*R*95*L*/*R*95*L*} mice (**Figure 3I**). GSEA further revealed an upregulation of inflammatory 219 signaling and downregulation of glycogen metabolism downstream signaling in 220 *Unc*93*b*1^{*R*95*L*/*R*95*L*} mice liver (**Figure 3J**). Immunofluorescence staining of glomeruli revealed 221 elevated IgG and C3 deposition in *Unc93b1*^{*R95L/R95L*} mice, while *Unc93b1*^{+/*R95L*} mice showed a 222 slight increase in IgG deposition (Figure 3K). These findings, aligned with PAS staining results, 223 confirm immune complex deposition and highlight the autoimmune pathology in 224 Unc93b1^{R95L/R95L} mice. 225

226

These analyses suggest that the *Unc93b1^{R95L}* mutation leads to widespread tissue inflammation and immune cell infiltration in multiple organs.

229

230 Differential activation of NF-κB and type I IFN pathways in various tissues

In the patient's PBMCs, we observed a more ubiquitous upregulation of genes in type I IFN
 pathway compared to NF-κB pathway, implying differential activation patterns of these

pathways through the dysfunctional UNC93B1/TLR axis in various tissues. To investigate the effects of the *UNC93B1* R95L mutation on inflammatory pathways in different tissues, we performed qPCR to measure the transcription levels of downstream genes in various tissues of the mice.

237

Interestingly, the *Unc93b1^{R95L}* mutation significantly enhanced the activation of NF-kB pathway 238 in the spleen and liver (Figure 3L, Supplemental Figure 3C). Additionally, upregulated genes 239 in splenocytes from Unc93b1^{R95L/R95L} mice exhibited enrichment in inflammatory and 240 autoimmune signaling pathways, implicating a specific contribution of splenocytes to immune 241 dysregulation (**Supplemental Figure 3D**). In contrast, the mutation significantly enhanced the 242 activation of the type I IFN pathway in the kidney and brain (Figure 3L). Despite the 243 morphological evidence of substantial lung tissue damage, qPCR results indicated that both 244 the NF-kB and type I IFN pathways were less pronounced in the lungs compared to other 245 tissues. The quadriceps muscle served as a negative control with no differential expression of 246 genes related to either pathway (Supplemental Figure 3E). 247

248

These findings suggest that the $Unc93b1^{R95L}$ mutation differentially affects NF- κ B and type I IFN signaling pathways across various tissues, contributing to the complex autoimmune and inflammatory phenotype observed in these mice.

252

253 Effects of Unc93b1^{R95L} mutation on immune cell populations in mice

Since the Unc93b1^{R95L} mutation affected inflammatory signaling in various tissues, we next 254 explored the impact of *Unc93b1*^{*R95L*} mutation on exact immune cell populations to elaborate 255 on its pathogenesis to SLE. We performed single-cell sequencing on murine spleen tissue 256 from Unc93b1^{R95L/R95L} and Unc93b1^{+/+} mice. Unsupervised clustering identified 28 cell 257 populations from murine splenocytes (Figure 4A, Supplemental Figure 4A). In view of 258 globally activated inflammatory response and autoimmune manifestation in the spleen of 259 *Unc93b1*^{*R95L/R95L*} mice, we carried out differential expression analysis among cell populations 260 between Unc93b1^{R95L/R95L} and Unc93b1^{+/+} mice. Amplified signaling in NF-kB pathway was 261

observed in myeloid cells and T cells from *Unc*93b1^{R95L/R95L} mice, with significant activation of 262 NF-kB through pathways like TNF signaling, which suggests that *Unc93b1*^{R95L} mutation drives 263 systemic inflammation state through T cells (Figure 4B). Additionally, we also detected 264 escalated production of immunoglobulin in B cells and plasma cells in Unc93b1^{R95L/R95L} mice, 265 with ascendant gene expression in the gene set about SLE pathogenesis, which implicated a 266 promoting role of the *Unc93b1*^{*R95L*} mutation in autoimmune pathology through B cells (**Figure** 267 **4C**). These results implicated a dysfunctinoal state of lymphocytes in *Unc93b1*^{*R95L/R95L*} mice, 268 269 which may contribute to the SLE pathogenesis.

270

To further investigate specific alterations of immune cells caused by the Unc93b1^{R95L} mutation, 271 we analyzed the immune phenotype in the spleen and peripheral blood of Unc93b1^{+/+} and 272 Unc93b1^{R95L/R95L} mice. Single-cell analysis of splenocytes revealed an increase of Treg cells, 273 follicular helper T (Tfh) cells, and plasma cells and a reduction of CD4⁺ T cells, naive CD8⁺ T 274 cells in the Unc93b1^{R95L/R95L} mice (Supplemental Figure 4B). Flow cytometry further 275 confirmed a disruption in lymphocyte composition, with an increase in germinal center (GC) B 276 277 cells, age-associated B cells (ABCs), follicular B cells, and plasma cells, indicating continuous activation of B cells in the spleens of *Unc93b1*^{*R95L/R95L*} mice (Figure 4, D-G, Supplemental 278 Figure 5, A-C), consistent with the high levels of autoantibodies found in the plasma of these 279 280 mice.

281

The number of Naive T cells were reduced, whereas effector memory T cells have increased, 282 suggesting a shift towards an activated or memory state, indicative of ongoing immune 283 activation and chronic inflammation characteristics of SLE (Figure 4, H and I, Supplemental 284 Figure 5, D and E). Additionally, expansions in NKT cells, double-negative T (DNT) cells, Treg 285 cells, effector Th (eTh) cells, and Th17 cells indicated the presence of inflammation and 286 autoimmune responses in Unc93b1^{R95L/R95L} mice. The rise in follicular helper T (Tfh) cells 287 aligns with the expansion in GC B cells, reflecting an active autoimmune response (Figure 4J, 288 289 Supplemental Figure 5F).

A reduction in NK cells, a cell type often impaired in SLE, suggests a dysfunction in immune 291 regulation. An increase in pDCs number can lead to excess production of interferon, promoting 292 293 inflammation and autoimmune responses in SLE. The decrease in mDCs, critical for antigen presentation and T cell activation, could be linked to abnormal antigen presentation 294 dysfunctions and immune dysregulation. An expansion in Ly6C-high monocytes is associated 295 with inflammation and tissue damage responses (Figure 4K, Supplemental Figure 5G). We 296 also observed a further concentrated MHC-II signaling and upregulation of ICAM signaling 297 from DCs to T cells (**Supplemental Figure 5, H and I**) in *Unc93b1*^{*R95L/R95L*} mice splenocytes 298 in single-cell analysis. 299

300

301 Collectively, these findings illustrate the altered immune landscape caused by the UNC93B1

302 **R95L** mutation, highlighting its role in promoting systemic inflammation and autoimmunity.

303

304 UNC93B1 R95L mutation enhances ligand binding to TLR7 by weakening the interaction 305 between UNC93B1 and TLR7

306 We next examined how the UNC93B1 R95L mutation affects TLR7 and TLR8 activation. The structure of the TLR7-UNC93B1 complex reveals that the UNC93B1 R95L mutation is located 307 within the H1 helix (residues 91-97) between the TM1 and TM2 transmembrane domains of 308 309 UNC93B1 (Figure 5A). This region directly interacts with two loop regions of the C-terminal LRR-CT domain of TLR7 and exhibits strong shape complementarity(17). In HEK293T cells, 310 immunoprecipitation and western blotting results indicated that the UNC93B1 R95L mutation 311 significantly weakened the interaction between UNC93B1 and both TLR7 and TLR8 (Figure 312 5, B and C). We further investigated the interactions between UNC93B1 and endogenous 313 TLR7. We generated RAW 264.7 cell lines stably expressing UNC93B1 (WT)-BirA* and 314 UNC93B1 (R95L)-BirA* and performed streptavidin pull-down. Western blotting results 315 showed that the UNC93B1 R95L mutation reduced the association between UNC93B1 and 316 317 cleaved forms of TLR7 (Figure 5D).

- 318
- 319 The weakened interaction did not alter TLR7 trafficking into endosomes, as receptor cleavage,

which occurs within endosomes, was unaffected (**Figure 5D**). We also isolated endosomes and lysosomes (late endosomes) from RAW 264.7 cells. Western blot analysis showed comparable levels of TLR7 in both wild-type and UNC93B1 R95L mutant cells (**Figure 5E**). Immunofluorescence microscopy revealed normal colocalization of TLR7 with Eea1 and Lamp1 in mouse BMDMs (**Figure 5, F and G**). These findings indicate that the UNC93B1 R95L mutation does not impact the trafficking of TLR7 from the ER to endosomes or from endosomes to lysosomes, suggesting a trafficking-independent role for UNC93B1.

327

The weakened interaction between UNC93B1 and TLR7 might alter the receptor conformation and increase the affinity for ligand binding, thereby activating the inflammatory pathway. To explore this, we conducted RNA pull-down experiments using mouse BMDCs. The results revealed that the UNC93B1 R95L significantly enhanced the binding of TLR7 to ssRNA (**Figure 5H**).

333

334 Discussion

Our study characterized a novel homozygous gain-of-function mutation p.R95L in *UNC93B1* leading to early-onset SLE. We also delineate distinct altered inflammatory responses amidst organs and immune cell populations during the SLE development caused by the *UNC93B1* R95L mutation. Limited by the heterogeneity of SLE, preventing SLE patients from sequalae during SLE progression is challenging. Our work enriched the spectrum of SLE pathogenic mutations, which could ameliorate the prognosis and disease development of SLE-like patients through early diagnosis and intervention.

342

UNC93B1 deficiency was firstly reported in 2006 with immunodeficiency and infections(16). Recently, a series of *UNC93B1* gain-of-function mutations were reported as pathogenic, predisposing to early-onset SLE and arthritis(23-27). These *UNC93B1* gain-of-function mutations exhibit dominant and recessive inheritance, however, some mutations are not rare variants in public database like gnomAD, which is unusual for monogenic disorders caused by gain-of-function mutations. Besides, some mutations, such as T93I, R336C, and V117L,

show dosage effects in phenotype presentation in both patients and animal models to different 349 extents. In our study, the UNC93B1 R95L mutation also displays additive effects on 350 351 autoimmune pathology and inflammatory response in different tissues. Though parents of patients with UNC93B1 gain-of-function mutations (R95L, E92G, I317M) have not presented 352 with SLE manifestation, current results suggest that gain-of-function UNC93B1 mutations, no 353 matter mono-allelic or bi-allelic, have potential for SLE development. The variable expressivity 354 and penetrance in the SLE caused by UNC93B1 gain-of-function mutations implicate a veiled 355 function of UNC93B1 in the innate immune, encouraging further investigation into the 356 mechanism of UNC93B1 in SLE pathogenesis beyond the regulation of TLR signaling. 357

358

As unrestricted intracellular nucleic-acid sensing leads to autoimmune or inflammatory 359 diseases(28-31), activation of intracellular TLRs is restrained within cells. TLR7 must be 360 transported to the endosome, where it is cleaved by proteases in the Z-loop region for 361 dimerization. TLR7 has two substrate-binding sites that recognize different substrates. The 362 sequential binding of these substrates induces conformational changes in TLR7, leading to 363 364 the close dimerization of the C-terminal TIR domain and initiating signal cascades. Subsequently, activated TLR7 is sorted into multivesicular bodies (MVBs) and late lysosomes 365 for degradation, terminating the signal. 366

367

UNC93B1 is involved not only in the transport of TLRs to endosomes but also in orchestrating 368 their functions. The D34A mutation in N-terminal domain of UNC93B1 can enhance the 369 response of TLR7 while inhibiting the response of TLR9, leading to systemic lethal 370 inflammation in mice(32). The C-terminal end of UNC93B1 interacts with syntenin-1 to 371 372 transport TLR7 to the phagosome, thereby terminating TLR7 activation. A mutation in the Cterminal region (PKP530-532) weakens this interaction with syntenin-1, promoting TLR7 373 activation and resulting in lupus-like symptoms in mice(33). Additionally, studies have shown 374 that the interaction between UNC93B1 and TLR9 in endosomes affects TLR9's ligand binding 375 376 and activation. The S282A point mutation disrupts the dissociation of UNC93B1 from TLR9 in endosomes, thereby impairing TLR9 signaling pathway activation in mouse macrophages and 377

378 dendritic cells(34).

379

380 In our study, both humans and mice carrying the UNC93B1 R95L homozygous mutation exhibited autoimmune and systemic inflammatory phenotypes. Based on our mechanistic 381 research and existing structural studies, we propose the following model (Figure 5I): in the 382 absence of ligand binding, TLR7 or TLR8 exists as a pre-dimer with the C-terminal TIR 383 domains far apart and the N-terminal domains unfavorable for ligand binding. Upon ligand 384 385 binding at the first binding site, the LRR domain undergoes a conformational change that promotes binding at the second site, further driving conformational changes that lead to the 386 387 aggregation of the C-terminal TIR domains and the initiation of downstream signaling pathways. The two-turn helix H1 (residues 91-97) formed between the TM1 and TM2 388 transmembrane domains of UNC93B1 directly contacts two loop regions of the TLR7 C-389 terminal LRR-CT domain, thus restricting TLR7 conformational changes and setting the 390 activation threshold of potentially self-reactive TLR7. The UNC93B1 R95L mutation weakens 391 the interaction between UNC93B1 and TLR7, enhancing the binding of the LRR domain to the 392 393 ligand and activating downstream signaling pathways. Recent studies reported that the E92G and T93I mutations also weaken the interaction between UNC93B1 and TLR7, leading to 394 TLR7 hyperactivation, likely through a similar mechanism. 395

396

Gain-of-function UNC93B1 mutations affecting innate immune through TLR7/8 but not other 397 endogenous TLRs have been well established in recent research. Our results support this 398 399 selective activation of TLRs in mutant UNC93B1-mediated inflammation. The interface 400 between UNC93B1 and TLR3 or TLR7 shows no differences, while the crystal structures of TLR7/8 display their distinct oligomerization states in ligand recognition(17, 35), implicating a 401 402 different mechanism in TLR signaling activation. TLR7 and TLR8 exist as pre-dimers even in the absence of ligand binding, with the regulation of antagonizing binding of UNC93B1 (in a 403 2:2 pattern) changing the conformation from inactive to active forms. In contrast, TLR3 and 404 405 TLR9 are monomers that interact with UNC93B1 in a 1:1 pattern without ligand binding. Upon stimulation, UNC93B1 dissociates, allowing the formation of active dimers. This may partially 406

407 explain why the UNC93B1 R95L mutation specifically promotes the activation of TLR7 and 408 TLR8, but has no effect on the activation of TLR3 and TLR9. These findings indicate the 409 diverse function of UNC93B1 in intracellular nucleic acid homeostasis, suggesting the 410 importance of future research on the dynamic balance of endosomal TLRs during SLE 411 development resulting from activated UNC93B1.

412

In our results, the UNC93B1 R95L mutation disrupts the interaction between UNC93B1 and 413 TLR7 as the previously characterized UNC93B1 H412R mutation does, however, UNC93B1 414 R95L still promotes TLR7/8 signaling. It was reported that the exogenous antigen processing 415 is abolished in UNC93B1^{H412R} mice(13). Based on the expression pattern of UNC93B1 in 416 protein atlas database, UNC93B1 is absent in T cells. Nevertheless, in our results, T cells from 417 the patient and animal model with the UNC93B1 R95L mutation display activated state in the 418 development of SLE through activation from DCs. Besides, we also observed specific 419 enrichment of immunoglobulin production and SLE signaling in B cells from Unc93b1^{R95L/R95L} 420 mice. Our results emphasize the importance of antigen presentation and humoral immunity in 421 422 the immune dysregulation mediated by UNC93B1 gain-of-function mutations.

423

To treat SLE caused by TLR7/8 hyperactivation due to UNC93B1 mutations, several 424 approaches may be considered. JAK inhibitors can block the JAK-STAT signaling pathway, 425 reducing inflammation and immune responses driven by cytokines such as IFN-α, which are 426 upregulated by TLR7/8 activation. Hydroxychloroquine (HCQ) inhibits endosomal acidification, 427 thus blocking TLR7/8 activation, and is already widely used in SLE treatment with a good 428 safety profile. Additionally, inhibitors targeting TLR7/8, MyD88, and IRAK1/4 can block the 429 TLR7 signaling pathway with better precision, reducing inflammation with fewer potential off-430 target effects. These inhibitors, though promising, are still largely undergoing clinical trials and 431 require further evaluation for long-term safety and efficacy. 432

433

434 Methods

435 Sex as a biological variable

Our study examined male and female mice, and sex-dimorphic effects are reported. The sex
of human involved in this study was not considered as a biological variable.

438

439 **Mice**

Unc93b1 R95L point mutation mice were generated in a C57BL/6J background using 440 CRISPR-Cas9-mediated gene editing technology. Genomic sequence 441 442 (ENSMUST00000162708.7) was obtained from Ensembl (https://ensembl.org/) and compared to human genes to ascertain sequence conservation. The sgRNA used was 5'-443 GCCATACTTCACCTCTCTGT-AGG-3'. The donor single-stranded oligonucleotide was: 5'-444 CAGCCTTGCCGTGAGCTTGTTTAGTTGTTCTGAGCCAGACTGATTAGAGCTCTCTACGA 445 TGCTCCCTGTCCCCAGGCCTCCTGCAGATGCAACTGATCCTGCACTATGATGAGACCT 446 ACCTCGAGGTGAAGTATGGCAACATGGGGCTGCCGGACATCGATAGCAAGATGCTGAT 447 GGGTATCAACGTGACGCCTATCGCTGCCCTGCTCTACACACCTGTGCTCATCAGGTGC 448 CAAACTTC-3'. The primers designed to amplify the region including the R95L mutation are 449 5'follows: Forward, 5'-CTGGGAACGGGAGTCTTGT-3'; 450 as Reverse, 451 AACAAGCAAGGCCTCTCTGC-3'.

452

Both male and female mice were used and their genders are indicated in the figures or figure legends. Within genotypes, mice were randomly allocated in all experiments. Data collection and analysis were not performed blind to the conditions of the experiments, except for histopathology. No animals or data points were excluded except contaminated samples.

457

458 Whole exome sequencing and Sanger sequencing

Genomic DNA from the patient and family members were isolated from peripheral blood using Maxwell RSC Whole Blood DNA Kit (Promega, AS1520). Whole exome sequencing (WES) and data analysis were performed as previously described(36, 37). ANNOVAR (2019Oct24) was used to annotate variants. Variants that appeared in gnomAD, Kaviar, dbSNP, and an inhouse database were filtered out. Variants were further filtered by homozygous inheritance. Sanger sequencing was used to confirm the *UNC93B1* variant identified by WES.

465

466 **Cell preparation, culture, and stimulation**

RAW 264.7, THP-1 and HEK293T cell lines were obtained from the American Type Culture 467 Collection. All cell lines tested negative for Mycoplasma contamination. PBMCs were 468 separated by Lymphocyte Separation Medium (MP, 50494) according to the manufacturer's 469 instructions. BMDMs were differentiated for 6-8 days in complete medium containing 50 ng/mL 470 M-CSF (PeproTech, 315-02). BMDCs were differentiated for 7 days in complete medium 471 472 containing 20 ng/mL GM-CSF (PeproTech, 315-03). For UNC93B1 overexpressing stable cell lines, a coding sequence expressing UNC93B1 and BirA* biotin ligase fusion protein 473 (UNC93B1-BirA*) was cloned into the retroviral MSCV-puro vector. THP-1 and RAW 264.7 474 cells were transduced with retroviruses expressing UNC93B1-BirA* and subjected to 475 puromycin selection. 476

477

RAW 264.7, HEK293T and BMDMs were grown in Dulbecco's Modified Eagle Medium (DMEM,
Gibco) supplemented with 10% FBS (Noverse) and penicillin/streptomycin (Gibco). THP-1,
PBMCs and BMDCs were grown in RPMI-1640 (Gibco) supplemented with 10% FBS and
penicillin/streptomycin.

482

R848 (Resiguimod, Sigmaaldrich, SML0196), a dual TLR7 and TLR8 synthetic agonist was 483 used to stimulate HEK293T (5 µg/mL), RAW 264.7 (25 ng/mL, 100 ng/mL), BMDCs (25 ng/mL), 484 and THP-1 (100 ng/mL) for the indicated amount of time. ssRNA40 (InvivoGen, tlrl-Irna40), 485 the natural ligand of the TLR7 and TLR8 was used to stimulate BMDCs (0.1 µM, 1 µM). 486 BMDMs (1 µM) for the indicated amount of time. CL307 (InvivoGen, tlrl-c307) a specific TLR7 487 agonist was used to stimulate RAW 264.7 (50 ng/mL) for the indicated amount of time. 488 Guanosine (Sigmaaldrich, G6264) was used to stimulate RAW 264.7 (200 µM) for the 489 indicated amount of time. TL8-506, a specific agonist for TLR8, was used to stimulate THP-1 490 (0.1 µg/mL, 1 µg/mL) for the indicated amount of time. Polyinosinic-polycytidylic acid (Poly(I:C), 491 492 Sigmaaldrich, P9582) a synthetic analog of double-stranded RNA (dsRNA) was used to stimulate HEK293T (50 µg/mL), RAW 264.7 (10 µg/mL), BMDCs (10 µg/mL), and THP-1 (10 493

µg/mL) for the indicated amount of time. LPS (Sigmaaldrich, L6529) was used to stimulate 494 RAW 264.7 (0.1 µg/mL) and THP-1 (0.1 µg/mL) for the indicated amount of time. Class A CpG 495 496 oligonucleotide ODN2216 (InvivoGen, tlrl-2216) was used to stimulate HEK293T (5 µM) for the indicated amount of time. Class B CpG oligonucleotide ODN2006 (InvivoGen, tlrl-2006) 497 was used to stimulate THP-1 (5 µM) for the indicated amount of time. Class A CpG 498 oligonucleotide ODN1585 (InvivoGen, tlrl-1585) was used to stimulate BMDCs (0.5 µM, 5 µM) 499 and RAW 264.7 (0.5 µM, 5 µM) for the indicated amount of time. Class B CpG oligonucleotide 500 ODN1668 (InvivoGen, tlrl-1668) was used to stimulate BMDMs (0.5 µM, 5 µM), BMDCs (0.5 501 μ M, 5 μ M) and RAW 264.7 (0.5 μ M, 5 μ M) for the indicated amount of time. Chloroquine (CQ, 502 Selleck, S6999), an autophagy/lysosome inhibitor, was used to treat RAW 264.7 (50 µM) for 503 the indicated amount of time. Enpatoran (M5049, Selleck, S9931) hydrochloride a dual TLR7/8 504 inhibitor, was used to treat RAW 264.7 (10 μ M) for the indicated amount of time. 505

506

507 **Expression plasmids and antibodies**

508 Human TLR3, TLR7, TLR8, TLR9 and wild-type UNC93B1 plasmids were constructed by PCR 509 amplification of UNC93B1 from the cDNAs of the THP-1 cell line, and then cloned into the 510 pLenti vector or MSCV-puro vectors made in-house, and the mutant plasmids were 511 constructed by site-directed mutagenesis.

512

513 For western blotting experiments, TLR7 (5632), TLR8 (11886), TLR9 (13674), and GAPDH 514 (5174) antibodies were purchased from Cell Signaling Technology. Flag (F3165) antibody was 515 from Sigma aldrich. UNC93B1 (PA5-20510) antibody was from Invitrogen. LAMP1 (ab25630) 516 antibody was from Abcam.

517

518 For immunofluorescence experiments, TLR7 (5632) and EEA1(3288) antibodies were 519 purchased from Cell Signaling Technology. LAMP1 (ab25630) antibody was purchased from 520 Abcam.

521

522 For flow cytometry experiments, V500 Rat Anti-Mouse CD45(30-F11) (561487), BV421

Hamster Anti-Mouse CD3e(145-2C11) (562600), FITC Rat Anti-Mouse CD4(RM4-5) (553046), 523 APC-Cy7 Rat Anti-Mouse CD8a(53-6.7) (557654), APC Rat Anti-Mouse CD19(1D3) (550992), 524 PE Rat Anti-Mouse CD138(281-2) (553714), BV605 CD317 (BST2) (747606), PE-Cy7 Rat 525 Anti-Mouse CD45R/B220(RA3-6B2) (552772), BUV496 CD11b (749864), BV750 F4/80 526 (747295), RB780 Ly-6C (755871), BUV395 I-A, I-E (569244), BUV805 CD44 (741921), 527 BUV563 CD62L (741230), BV786 Rat Anti-Mouse CD25(PC61) (564023), BV650 Rat Anti-528 Mouse IL-17A (TC11-18H10) (564170), BUV737 Rat Anti-Mouse CD21/CD35(7G6) (612810), 529 530 RB545 CD23 (756344), BV480 CD95 (746755), BUV615 CD49b (751052), BV711 CD279 (PD-1) (744547), PE-CF594 Rat Anti-Mouse CD185 (CXCR5)(2G8) (562856), and R718 Ly-531 6G (567039) antibodies were purchased from BD Biosciences. PE-CYN5 FOXP3 (15-5773-532 82), PE-CYN5 FOXP3 (15-5773-82), and PERCPEF710 BCL-6 (46-5453-82) antibodies were 533 purchased from Invitrogen. Brilliant Violet 570 anti-mouse CD11c (117331) and APC anti-534 mouse TNF (506308) antibodies were purchased from Biolegend. 535

536

537 Dual-luciferase reporter assay

The NF-κB firefly reporter plasmid (pGL4.32 [luc2P/NF-κB-RE/Hygro] and the Renilla luciferase expression plasmid (pRLCMV-Renilla) were co-transfected along with TLRs and UNC93B1 expression plasmids into HEK293 cells. After 24 hours of transfection and indicated treatment, cells were harvested, and luciferase activity was measured using the Dual Luciferase Reporter Assay Kit (Vazyme, DL101-01). Data were calculated as fold induction by normalizing firefly luciferase activity to Renilla luciferase activity.

544

545 **RNA extraction and quantitative PCR**

546 TRIzol reagent (Invitrogen, 15596026) and RNeasy Mini kit (Qiagen, 74104) were applied to 547 extract total RNA from cultured cells and murine tissues. One microgram of RNA was reverse-548 transcribed using the PrimeScript RT Reagent Kit with gDNA Eraser (Perfect Real Time) 549 (Takara, RR047A). Gene expression analyses were performed using 2X Universal SYBR 550 Green Fast qPCR Mix (ABclonal, RK21203) on ROCHE 480II. Relative mRNA expression was 551 analyzed by the $\Delta\Delta C_t$ method and normalized to *ACTB* (for human samples) or *Actb* (for

552 mouse samples).

553

554 **RNA sequencing**

RNA sequencing libraries were generated using the NEBNext Ultra RNA Library Prep Kit for 555 Illumina (New England Biolabs) following the manufacturer's protocol. The libraries were then 556 sequenced on an Illumina NovaSeq platform to obtain high-throughput sequencing data. The 557 resulting reads were mapped to the reference genome, and featureCounts was utilized to 558 559 quantify the number of reads mapped to each gene. For differential expression analysis, the DESeq2 (version 1.44.0) and clusterProfiler (version 4.12.0) R package was employed, which 560 561 involved normalization of read counts, statistical testing, and identification of differentially expressed genes between the experimental conditions. Gene set scores in differential 562 expression analysis of RNA sequencing data are summing of z-scores of each gene in the 563 gene set. Z-score of each gene in the gene set is calculated relative to the mean and standard 564 deviation Healthy controls. Gene msigDB (https://www.gsea-565 of sets from msigdb.org/gsea/msigdb) are used for analysis. 566

567

568 Single-cell RNA sequencing

For human PBMCs, 8,000-10,000 single cells for each sample were captured and barcoded 569 with a 10x Genomics Chromium console, while the library of about 10,000 cells from murine 570 spleen samples were constructed by MGI DNBelab C-TaiM4. The barcoded complementary 571 DNA was amplified and sequenced by Illumina Novaseq and MGI DNBSEQ-T7 for human 572 573 PBMC and murine samples, respectively. Novaseg sequencing data was processed with cellranger (10X Genomics, version 6.1.1), while DNGSEQ-T7 sequencing data was processed 574 with DNBC4tools (MGI, version 2.1.1). Downstream guality control, processing and differential 575 expression analysis were performed by Seurat package (version 4.2.0) and harmony package 576 (version 1.2.0) in R. 577

578

579 Flow cytometry analysis

580 The mice spleen single-cell suspensions were prepared using the plunger end of the syringe

and filtered using 100 µm and 40 µm strainers with 2% FBS in PBS. The collected filtrates were centrifuged at 350 g for 5 min. The cell pellet was suspended in 5 mL RBC lysis buffer, incubated for 4 min at 25 °C and then mixed with 10 mL of PBS with 2% FBS. The splenocytes were resuspend in PBS after centrifugation at 350 g for 5 min. Whole blood cells were collected from heart blood and incubated with 10 mL RBC lysis buffer for 5 min at 25 °C, and then mixed with 20 mL PBS with 2% FBS. The whole blood cells were resuspended in PBS after centrifugation at 350 g for 5 min.

588

589 For flow cytometry analysis, 1*10⁶ cells were incubated with Fixable Viability Stain 440UV (BD 590 Biosciences, 566332) for 15 min at room temperature protected from light. Washed twice with 591 fluorescence-activated cell sorting (FACS) buffer (0.5% BSA in PBS) and stained with cell-592 surface markers for 1 hours on ice. For fixation and permeabilization, 1.6% PFA and 40% 593 methanol were used. The cells were then washed twice and stained with intracellular 594 antibodies for 1 hours on ice. All events were acquired on Cytek Aurora and analyzed by 595 SpectroFlo and FlowJo_v.10.8.1. Gating strategy is shown in Supplemental Figure 6.

596

597 ELISA and CBA

Levels of cytokines IL-6, IFN-α and chemokine IP-10 in human serum were determined by Cytometric Bead Array (BD Bioscience). All data were analyzed by FCAPArray V3 software (BD Biosciences). Macrophage colony-stimulating factor (M-CSF) (MULTISCIENCES, EK1144), Granulocyte colony-stimulating factor (G-CSF) (MULTISCIENCES, EK169) concentrations in human serum were measured by enzyme-linked immunosorbent assay (ELISA) kit.

604

The ELISA kits used for Cxcl1 (EK286), II-6 (EK206), CRP (EK294) quantification in murine
plasma were purchased from Multisciences. ANA (ml002245), II-1β (ml098416) and C3
(ml002033) quantification in murine plasma were purchased from Mlbio.

608

609 For detecting autoantibodies in murine plasma, coating antigens (1 μg DNA or RNA) were

diluted in Coating Buffer and added to an ELISA plate, then incubated overnight at 4 °C. The plate was blocked with Diluent Buffer for 1 hour at room temperature. Samples and standards were diluted in Diluent Buffer and incubated for 2 hours at room temperature. Detection antibodies were added and incubated for 1 hour, followed by HRP conjugate (Beyotime, A0216) for 30 minutes, both at room temperature. TMB substrate (Beyotime, P0209) was added and incubated for 30 minutes, then stop solution (Beyotime, P0215) was added. Absorbance was measured at 450 nm using a microplate reader.

617

618 Western blotting and Immunoprecipitation

Cells were lysed in ice-cold lysis buffer (50 mM Tris - HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA,
1% digitonin) supplemented with Complete Mini EDTA-free (4693159001, Roche) and
PhosSTOP (4906837001, Roche). Protein concentration was measured by a BCA protein
assay kit (23225, Thermo Fisher). Immunoblotting was conducted as described previously
with specific antibodies(38, 39).

624

For immunoprecipitation, cell lysates were combined with immunomagnetic beads for 4 hours.
Then, immunocomplexes were washed five times using the lysis buffer and subjected to
western blot analysis.

628

The proximity-labeling BioID approach, as previously described(40), was used to detect the 629 interactions between UNC93B1 and TLR7. RAW 264.7 cells stably expressing UNC93B1 630 (WT)-BirA* /UNC93B1 (R95L)-BirA* were incubated for 24 hours in complete media 631 supplemented with or without 20 µM biotin. After three washes with PBS, cells were lysed in 632 633 lysis buffer (50 mM Tris-Cl, 137 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% Glycerol) supplemented with Complete Mini EDTA-free (4693159001, Roche). Lysed cells were 634 centrifuged under 14,000 g for 10 min at 4 °C. Supernatants were then incubated with 20 µL 635 streptavidin agarose beads for 24 h at 4 °C. Beads were pelleted by centrifugation at 2,000 636 rpm for 2 min and eluted with Elute Buffer (1.5x SDS protein sample buffer containing 1 mM 637 biotin) for western blot analysis. 638

639

640 Immunofluorescence

For immunofluorescence (IF) staining of murine kidney tissue cryosections, the sections were first fixed and permeabilized, followed by blocking with 10% normal goat serum (NGS, Beyotime, C0265) in PBS for 1 hour. Mouse antibodies diluted in 10% NGS/PBS (IgG 1:200; C3 1:200) were applied to the sections and incubated overnight at 4°C. Secondary antibodies diluted at 1:500 in 10% NGS/PBS were then incubated with the sections at room temperature for 1 hour.

647

For IF staining of cultured cells, cells were plated onto glass coverslips and allowed to settle 648 overnight. Cells were fixed with methanol for 5 min at -20 °C and permeabilized with 100 µM 649 digitonin-PBS for 5 min at RT. After washing 3 times with PBS, cells were blocked in 10% NGS 650 (Beyotime, C0265) in PBS for 30min. Slides were stained in blocking buffer with primary 651 antibodies overnight at 4 °C. After washing 3 times with PBS, slides were incubated for 1 hour 652 with secondary antibodies in blocking buffer at RT. After washing 3 times with PBS, slides were 653 654 mounted using Mounting Medium with DAPI (ab104139, abcam). Images were acquired and quantified by ZEISS LSM 900. 655

656

657 Immunohistochemistry

Freshly dissected murine spleens, kidneys, livers and lungs were fixed in 4% paraformaldehyde (Sigma-Aldrich, P6148) for 16 hours at 4 °C, embedded with paraffin and stained with hematoxylin/eosin (H&E) or periodic acid-Schiff (PAS). The tissue slides were scanned using Aperio ScanScope XT scanner (Leica). Glomerular size was analyzed in a blinded manner using NDP.view 2. Glomerular size was determined from an area with at least 10 glomeruli per kidney section from at least 3 mice in each group.

664

665 Author contributions

666 QZ, PT and XY designed the study, directed, and supervised the research. XH, RW, SO, and 667 QW contributed equally. PT, RW, QW, WD, YZ, OX and HY performed experiments. XH

analyzed the data. QZ and SO enrolled the patient, collected, and interpreted clinical
 information. QZ, PT, XH, and RW wrote the manuscript, with input from others. All authors
 contributed to the review and approval of the manuscript.

671

672 Acknowledgments

We thank the patient and the unaffected controls for their support during this research study. 673 We thank the core facility of the Life Sciences Institute, Zhejiang University and core facilities 674 of Zhejiang University Medical Center/Liangzhu laboratory for technical assistance. The works 675 of QZ were supported by grants 82225022, 32141004 and 32321002 from The National 676 677 Natural Science Foundation of China. The works of X.Y. were supported by the Major Program of the National Natural Science Foundation of China (82394424), the National Natural Science 678 Foundation of China (82471844), the Hundred-Talent Program of Zhejiang University and 679 Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2021R01012). 680 The works of PT were supported by grants 82201926 and 82471814 from The National Natural 681 Science Foundation of China, BX2021259 and 2021M702852 from China Postdoctoral 682 683 Science Foundation. The works of RW were supported by grant 82300893 from The National Natural Science Foundation of China. 684

685

686 Competing interests

687 Authors declare that they have no competing interests.

688

689 Statistics

Statistical analyses were performed using GraphPad Prism 8. All values were as mean \pm SEM and calculated from the average of at least three independent biological replicates unless specifically stated. Statistical differences were evaluated using the Student's *t* test (unpaired and two-tailed) for comparisons between two groups or ANOVA for comparisons of more than two groups. In all tests, a 95% confidence interval was used, for which *P* < 0.05 was considered a significant difference. *P* values obtained in next-generation sequencing were adjusted by FDR using R Software (R version 4.4.1).

697					
698	Study approval				
699	This study involves human participants and was approved by the institutional review boards				
700	of the Children's Hospital of Zhejiang University School of Medicine in China. Participants				
701	provided written informed consent to participate in the study before taking part.				
702	Mice were bred and maintained in specific-pathogen-free conditions at the Laboratory Animal				
703	Center of Zheijang University, with normal diet, 12 h light/dark cycle, 20-26 °C and humidity of				
704	40-70% Experimentation was approved by the Institutional Animal Care and Lise Committee				
704					
705	or znej	liang University.			
706					
707	Data a	nd materials availability			
708	All data	a are available in the main text or the Supplemental materials.			
709					
710	Refere	ences			
711	1.	Omarjee O, et al. Monogenic lupus: Dissecting heterogeneity. Autoimmun Rev.			
712		2019;18(10):102361.			
713	2.	Demirkaya E, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and			
714		Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med. 2020;9(3).			
715	3.	O'Neill LA, and Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor			
716		signalling. <i>Nat Rev Immunol.</i> 2007;7(5):353-64.			
717	4.	Fitzgerald KA, and Kagan JC. Toll-like Receptors and the Control of Immunity. Cell.			
718		2020;180(6):1044-66.			
719	5.	Gantier MP, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human			
720		macrophages. <i>J Immunol.</i> 2008;180(4):2117-24.			
721	6.	Hornung V, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of			
722		human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J			
723	7	With Sovers COVID 19			
725	1.	Jama 2020-324/(7)-663-73			
726	8	Brown G1 et al TLR7 gain-of-function genetic variation causes human lunus <i>Mature</i>			
727	0.	2022:605(7909):349-56			
728	9	David C et al Interface Gain-of-Function Mutations in TLR7 Cause Systemic and Neuro-			
729	0.	inflammatory Disease. J Clin Immunol. 2024:44(2):60.			
730	10.	Stremenova Spegarova J. et al. A de novo TLR7 gain-of-function mutation causing severe			
731		monogenic lupus in an infant. <i>J Clin Invest.</i> 2024;134(13).			
732	11.	Cervantes JL, et al. TLR8: the forgotten relative revindicated. <i>Cell Mol Immunol.</i> 2012;9(6):434-8.			
733	12.	Aluri J, et al. Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of			

734		function. <i>Blood.</i> 2021;137(18):2450-62.
735	13.	Tabeta K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling
736		via Toll-like receptors 3, 7 and 9. Nat Immunol. 2006;7(2):156-64.
737	14.	Itoh H, et al. UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated
738		signaling. <i>PLoS One.</i> 2011;6(12):e28500.
739	15.	Kim YM, et al. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature.
740		2008;452(7184):234-8.
741	16.	Casrouge A, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science.
742		2006;314(5797):308-12.
743	17.	Ishida H, et al. Cryo-EM structures of Toll-like receptors in complex with UNC93B1. Nat Struct Mol
744		<i>Biol.</i> 2021;28(2):173-80.
745	18.	Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology
746		Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12.
747	19.	Postal M, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin
748		<i>Immunol.</i> 2020;67:87-94.
749	20.	Reizis B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. Immunity.
750		2019;50(1):37-50.
751	21.	Granot T, et al. Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over
752		Human Life. <i>Immunity.</i> 2017;46(3):504-15.
753	22.	Shin KS, et al. Monocyte-Derived Dendritic Cells Dictate the Memory Differentiation of CD8(+) T
754		Cells During Acute Infection. Front Immunol. 2019;10:1887.
755	23.	Rael VE, et al. Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated
756		autoimmunity in mice and humans. J Exp Med. 2024;221(8).
757	24.	David C, et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus
758		and chilblain lupus. <i>J Exp Med.</i> 2024;221(8).
759	25.	Al-Azab M, et al. Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus
760		erythematosus. <i>Nat Immunol.</i> 2024;25(6):969-80.
761	26.	Mishra H, et al. Disrupted degradative sorting of TLR7 is associated with human lupus. Sci Immunol.
762		2024;9(92):eadi9575.
763	27.	Wolf C, et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci Immunol.
764		2024;9(92):eadi9769.
765	28.	Rodero MP, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat
766		<i>Commun.</i> 2017;8(1):2176.
767	29.	Al-Mayouf SM, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic
768		lupus erythematosus. <i>Nat Genet.</i> 2011;43(12):1186-8.
769	30.	Crow YJ, et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-
770		Goutières syndrome at the AGS1 locus. <i>Nat Genet.</i> 2006;38(8):917-20.
771	31.	Peng J, et al. Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis
772		due to RIG-I Hyperactivation. JAm Soc Nephrol. 2023;34(2):258-72.
773	32.	Fukui R, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7
774		and 9 trafficking. <i>Immunity.</i> 2011;35(1):69-81.
775	33.	Majer O, et al. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity.
776		<i>Nature.</i> 2019;575(7782):366-70.
777	34.	Majer O, et al. Release from UNC93B1 reinforces the compartmentalized activation of select TLRs.

778		Nature. 2019;575(7782):371-4.
779	35.	Tanji H, et al. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic
780		ligands. <i>Science.</i> 2013;339(6126):1426-9.
781	36.	Zhou Q, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J
782		Med. 2014;370(10):911-20.
783	37.	Zhou Q, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an
784		early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67-73.
785	38.	Tao P, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.
786		Nature. 2020;577(7788):109-14.
787	39.	Wang Y, et al. Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-
788		targeted drug design. <i>Immunity.</i> 2023;56(7):1485-501.e7.
789	40.	Roux KJ, et al. A promiscuous biotin ligase fusion protein identifies proximal and interacting
790		proteins in mammalian cells. J Cell Biol. 2012;196(6):801-10.
791		
792		







793

Figures



- 796 **R95L** mutation.
- (A) Clinical images displaying skin rashes on the patient's back (left) and hip (right). 797
- (B) Pedigree of the patient with a homozygous variant c.284G>T (NM 030930), p.R95L in 798
- 799 UNC93B1.
- 800 (C) Validation of the homozygous variant in UNC93B1 using Sanger sequencing.
- (D) The evolutionary conservation of the arginine at position 95 in UNC93B1 across species. 801

(E) Serum Levels of cytokines IL-6, IFN- α , and chemokine IP-10 in the patient (P) and healthy controls (HCs, n = 6) were detected by CBA.

- (F) Serum Levels of colony-stimulating factors M-CSF and G-CSF in the patient (P) and
- healthy controls (HCs, n = 6) were detected by ELISA.
- 806 (G) Transcription level of NF-κB and type I IFN pathways in PBMCs from the patient (P) and
- healthy controls (HC, n = 3). Analysis of each sample was performed in duplicate.
- 808 (H) qPCR analysis of NF-κB and type I IFN pathways related genes in PBMCs from the patient
- (P) compared with healthy controls (HCs, n = 5).
- (I) Uniform manifold approximation and projection (UMAP) visualization and marker-based
- annotation of 18 cell subtypes from the patient and healthy controls (HCs, n = 3).
- (J) UMAP visualization of the target pathway scoring in the patient and healthy controls (HCs,
- n = 3). Upper, pathway scoring based on genes on NF- κ B signal transduction gene set in
- Gene Ontology database; bottom, pathway scoring based on genes on response to type I IFN
- gene set in Gene Ontology database. Scores were generated based on Seurat
 Addmodulescore method.
- (K) Expression levels of essential genes in NF-κB and type I IFN pathways in various immune
- cells among the patient and healthy controls (HCs, n = 3).
- (L) Enrichment of upregulated pathways of differential expressed gene in patient's DCs basedon GSEA.
- 821



822

Figure 2. UNC93B1^{R95L} mutation promotes inflammation through TLR7/TLR8 activation.
(A) NF-κB luciferase assays in HEK293T cells co-transfected TLR7 (left) or TLR8 (right) with

different UNC93B1 expression plasmids, treated as indicated (n = 3 biological replicates). 825 Data represent mean ± SEM; **, *P* < 0.01; ***, *P* < 0.001; two-tailed unpaired Student's *t* test.

826

827 EV: empty vector; WT: wild-type UNC93B1; R95L: R95L mutant; HR: H412R mutant.

(B) qPCR analysis of IL8 transcription level in HEK293T cells co-transfected TLR7 (left) or 828 TLR8 (right) with different UNC93B1 expression plasmids, treated as indicated (n = 3829 biological replicates). Data represent mean ± SEM; ***, P < 0.001; two-tailed unpaired 830 831 Student's *t* test.

(C) gPCR analysis of IL8 in HEK293T cells co-transfected TLR3 with different UNC93B1 832 expression plasmids, treated as indicated (n = 3 biological replicates). Data represent mean 833 ± SEM; two-tailed unpaired Student's t test. EV: empty vector; WT: wild-type UNC93B1; R95L: 834 835 R95L mutant; HR: H412R mutant.

(D) NF-κB luciferase assay in HEK293T cells co-transfected TLR9 with different UNC93B1 836 expression plasmids, treated as indicated (n = 3 biological replicates). Data represent mean 837 ± SEM; *, *P* < 0.05; two-tailed unpaired Student's *t* test. WT: wild-type UNC93B1; R95L: R95L 838 mutant. 839

840 (E) qPCR analysis of *IL1B*, *IL6*, *IL8* and *TNF* transcription levels in THP-1 expressing the WT or R95L mutant UNC93B1 treated with various TLRs agonists (n = 3 biological replicates). 841 Data represent mean ± SEM; **, *P* < 0.01; ***, *P* < 0.001; two-tailed unpaired Student's *t* test. 842 843 (F, G) Intracellular cytokine staining of Tnf in mouse RAW 264.7 expressing the WT or R95L mutant UNC93B1, and treated with various TLRs agonists or inhibitors. 844 (H, I) qPCR analysis of NF-κB (H) and type I IFN (I) pathways related genes transcription in 845

BMDCs from indicated mice treated with various TLRs agonists(n = 5 mice per group). Data 846

represent mean ± SEM; **, P < 0.01; ***, P < 0.001; two-tailed unpaired Student's t test. 847





849

Figure 3. Mice with Unc93b1^{R95L} mutation develop systemic inflammation and 850 autoimmune pathology. 851

substitution 852 (A) Sanger sequencing showing the amino acid Unc93b1. ENSMUST00000162708.7: c.283 285delinsCTC, p.R95L in homozygous knock-in mice. Wild 853 type (+/+), heterozygous (+/R95L), and homozygous (R95L/R95L) are indicated. 854

- (B) Body weight of $Unc93b1^{+/+}$, $Unc93b1^{+/R95L}$ and $Unc93b1^{R95L/R95L}$ mice.
- (C) Representative images of splenomegaly and normalized spleen weight to body weight
- (spleen index) of 12-wk-old mice (n = 5 per group). Data represent mean \pm SEM; **, P < 0.01;
- 858 ***, *P* < 0.001; one-way ANOVA.
- (D) Plasma levels of anti-DNA, anti-RNA, ANA, CRP and C3 in the indicated mice were
- detected using ELISA (n = 5 per group). Data represent mean ± SEM; *, *P* < 0.05; **, *P* < 0.01;
- 861 ***, *P* < 0.001; one-way ANOVA.
- (E) Plasma levels of II-1 β , II-6 and chemokine Cxcl1 in the indicated mice were detected using
- 863 ELISA (*Unc93b1*^{+/+}, n = 10; *Unc93b1*^{+/R95L}, n = 6; *Unc93b1*^{R95L/R95L}, n = 6). Data represent mean
- 864 ± SEM; **, *P* < 0.01; ***, *P* < 0.001; one-way ANOVA.
- (F) H&E staining of the spleen from indicated mice (left). Normalized white pulp was calculated
- (right). (*Unc93b1^{+/+}*, n = 10; *Unc93b1^{+/R95L}*, n = 6; *Unc93b1^{R95L/R95L}*, n = 6). Data represent
 mean ± SEM; *, *P* < 0.05; ***, *P* < 0.001; one-way ANOVA.
- 868 (G) PAS staining of the kidney from indicated mice (left). Glomerulus area was calculated
- 869 (right). (*Unc93b1*^{+/+}, n = 10; *Unc93b1*^{+/R95L}, n = 6; *Unc93b1*^{R95L/R95L}, n = 6).Data represent
- 870 mean ± SEM; ***, *P* < 0.001; one-way ANOVA.
- (H) PAS staining of the lung and liver from indicated mice.
- (I) Short fasting blood glucose levels of the indicated mice (n = 8 per group). Data represent
- 873 mean \pm SEM; **, *P* < 0.01; two-tailed unpaired Student's *t* test.
- (J) Top 15 enriched pathways of differential expressed genes in murine hepatocytes from the
 Unc93b1^{+/+}, and Unc93b1^{R95L/R95L} mice.
- (K) Representative immunofluorescent images of IgG and C3 in glomerulus from the indicated
- mice(left). IgG (top) and C3 (bottom) staining in individual glomerulus was quantified (n = 30
- glomerulus from three mice per group). Data represent mean \pm SEM; ***, *P* < 0.001; one-way
- 879 **ANOVA**.
- (L) qPCR analysis of NF-κB and type I IFN pathways related genes in the spleen, kidney, liver,
- and brain from the indicated mice (spleen, kidney and liver, n = 8-10 per group; brain,n = 4-7
- per group). Data represent mean \pm SEM; **, P < 0.01; ***, P < 0.001; one-way ANOVA.
- 883



884



(A) UMAP visualization and marker-based annotation of 28 cell subtypes from splenocytes of 886 $Unc93b1^{R95L/R95L}$ and $Unc93b1^{+/+}$ mice (n = 3 mice per group). NKT, natural killer T cell; gdT, 887 gamma-delta T cell; Treg, regulatory T cell; MZ B, marginal zone B cell; Fo B, follicular B cell; 888 DC, dendritic cell; MDP, myeloid dendritic progenitor. 889 (B) Upregulated inflammatory signal in *Unc93b1*^{R95L/R95L} mice. Left, pathway scoring of NF-κB 890

signal transduction gene set in Gene Ontology database; right, GSEA plot shows upregulated 891

TNF signaling pathway in murine splenic T cells. Pathway score is calculated by the Seurat
Addmodulescore method.

- (C) Upregulated autoimmune characteristics in *Unc93b1^{R95L/R95L}* mice. Left, pathway scoring
 of immunoglobulin production gene set in Gene Ontology database; right, GSEA plot shows
 upregulated SLE signaling pathway in murine splenic B cells. Pathway score is calculated by
- the Seurat Addmodulescore method.
- (D-G) Splenic germinal center B cells (GC B) (D), age-associated B cells (ABC) (E), marginal
- zone B cells (MZ B) (F), follicular B cells (F), and plasma cells (G) distribution are indicated by
- 900 FACS plots and percentages (n = 11 mice per group). Data represent mean ± SEM; ***, P <
- 901 0.001; two-tailed unpaired Student's *t* test.
- 902 (H, I) Splenic CD4⁺ T cells (H) and CD8⁺ T cells (I) activation are indicated by FACS plots and
- 903 percentages (n = 8 mice per group). Data represent mean \pm SEM; **, P < 0.01; ***, P < 0.001;
- 904 two-tailed unpaired Student's *t* test.
- 905 (J) Flow cytometric analysis of splenic T cell populations from indicated mice (n = 6-8 mice per
- 906 group). Data represent mean \pm SEM; **, P < 0.01; ***, P < 0.001; two-tailed unpaired Student's 907 *t* test.

908 (K) Flow cytometric analysis of splenic NK, pDCs, mDCs and monocytes populations from 909 indicated mice (NK, n = 6-7 mice per group; pDCs, mDCs and monocytes, n = 11 mice per 910 group). Data represent mean \pm SEM; *, *P* < 0.05; **, *P* < 0.01; ***, *P* < 0.001; two-tailed 911 unpaired Student's *t* test.





915 interaction.

913

- 916 (A) The structure of TLR7 and UNC93B1 complex (PDB: 7CYN) shows H1 helix (residues 91-
- 917 97) of UNC93B1 directly contacting two loop regions of the C-terminal LRR-CT domain of
- 918 TLR7. Protein structural analysis was executed with Pymol.
- (B) Flag-immunoprecipitation and western blot analyses of UNC93B1 and TLR7 (left)/TLR8
- 920 (right) interaction in HEK293T cells.
- 921 (C) TLR8-immunoprecipitation and western blot analyses of UNC93B1 and TLR8 interaction
- 922 in HEK293T cells.
- (D) BioID and western blot analyses of UNC93B1 and TLR7 interaction in RAW 264.7 cells.
- 924 (E) Immunoblots of TLR7 in endosomes and late endosomes/lysosomes from RAW 264.7
- 925 cells expressing the WT or R95L mutant UNC93B1.
- 926 (F, G) Representative immunofluorescent images (F) and quantification of the colocalization
- 927 between TIr7 and Lamp1 or Eea1 in BMDMs from the indicated mice (G) (n = 14-18 cells per
- group). Data represent mean ± SEM; two-tailed unpaired Student's *t* test.
- 929 (H) RNA pull-down and western blot analyses of ssRNA binding affinity of TIr7 in BMDCs.
- 930 (I) Graphic model of how R95L mutation affect UNC93B1/TLR axis and downstream signaling.





Supplemental Figure 1. Inflammatory signaling activated in the patient with UNC93B1 933

R95L mutation. 934

- (A) Comparison of gene set score of inflammatory response genes in msigDB and NF-kB and 935
- type I IFN response genes between patient and healthy controls (HCs, n = 3). 936
- (B) Top 15 enrichment of upregulated pathways of differential expressed gene in patient based 937
- on GSEA. 938
- (C) Marker genes used for cluster annotation in human PBMCs single-cell RNA sequencing. 939
- (D) Top 15 enrichment of upregulated pathways of differential expressed gene in patient's T 940
- cells based on GSEA. 941
- 942

medRxiv preprint doi: https://doi.org/10.1101/2024.09.11.24313360; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



943



946 (A) qPCR analysis of NF-κB and type I IFN pathways related genes transcription in RAW 264.7 947 cells treated with various TLRs agonists (n = 3 biological replicates). Data represent mean ± 948 SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; two-tailed unpaired Student's *t* test.

949 (B) qPCR analysis of NF-κB and type I IFN pathways related genes transcription in BMDMs 950 from indicated mice treated with various TLRs agonists (n = 3-5 mice per group). Data 951 represent mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; two-tailed unpaired Student's

952 *t* test.





954

Supplemental Figure 3. Mice with Unc93b1^{R95L} mutation develop systemic inflammation 955

and autoimmune pathology. 956

957 (A) Normalized kidney, liver, lung weight to body weight of 12-wk-old mice (female, n = 4 per

- group; male, n = 5 per group). Data represent mean ± SEM; **, P < 0.01; one-way ANOVA.
- 959 (B) PAS staining of the kidney from indicated mice.
- 960 (C) Comparison of gene set score of NF-κB and type I IFN response genes and GSEA in TNF
- 961 signaling pathway of liver and spleen tissues from the *Unc93b1*^{+/+} and *Unc93b1*^{R95L/R95L} mice.
- 962 NES, normalized enrichment score.
- 963 (D) Top 15 enrichment of upregulated pathways of differential expressed gene between the
- 964 *Unc93b1*^{+/+} and *Unc93b1*^{*R95L/R95L*} mice based on GSEA. NES, normalized enrichment score.
- 965 (E) qPCR analysis of NF-κB and type I IFN pathways related genes in the spleen, kidney, liver,
- 966 brain, lung and quadricep from the indicated mice (spleen, kidney and liver, n = 8-10 per group;
- 967 brain, lung and quadricep, n = 4-7 per group). Data represent mean ± SEM; *, P < 0.05; **, P
- 968 < 0.01; ***, *P* < 0.001; one-way ANOVA.



970

971 Supplemental Figure 4. Single-cell sequencing analysis of murine splenocytes.

972 (A) Marker genes used for cluster annotation in murine splenocytes single-cell RNA
973 sequencing.

974 (B) Cell ratio of different cell clusters among murine splenocytes based on single-cell 975 sequencing from the $Unc93b1^{+/+}$ and $Unc93b1^{R95L/R95L}$ mice.

976 NKT, natural killer T cell; gdT, gamma-delta T cell; Treg, regulatory T cell; MZ B, marginal zone

977 B cell; Fo B, follicular B cell; DC, dendritic cell; MDP, myeloid dendritic progenitor.





979



(A-C) germinal center B cells (GC B) (A), age-associated B cells (ABC) (B), marginal zone B 982 cells (MZ B) and follicular B cells (C) distribution in peripheral blood of Unc93b1^{R95L/R95L} and 983 *Unc*93*b*1^{+/+} mice are indicated by FACS plots and percentages (n = 7 mice per group). Data 984

represent mean ± SEM; **, P < 0.01; ***, P < 0.001; two-tailed unpaired Student's t test. 985

(D, E) Peripheral blood CD4⁺ T cells (D) and CD8⁺ T cells (E) activation are indicated by FACS 986 plots and percentages (n = 7 mice per group). Data represent mean \pm SEM; ***, P < 0.001; 987

two-tailed unpaired Student's *t* test. 988

(F) Flow cytometric analysis of peripheral blood T cell populations from indicated mice (n = 7 989 mice per group). Data represent mean ± SEM; **, *P* < 0.01; ***, *P* < 0.001; two-tailed unpaired 990

991 Student's *t* test.

992 (G) Flow cytometric analysis of peripheral blood pDCs, mDCs and monocytes populations 993 from indicated mice (n = 7 mice per group). Data represent mean \pm SEM; *, *P* < 0.05; **, *P* <

994 0.01; two-tailed unpaired Student's *t* test.

(H) Cell communication of MHC-II signaling in splenocytes from the *Unc93b1^{+/+}* and *Unc93b1^{R95L/R95L}* mice. NKT, natural killer T cell; gdT, gamma-delta T cell; Treg, regulatory T
cell; MZ B, marginal zone B cell; Fo B, follicular B cell; DC, dendritic cell; MDP, myeloid
dendritic progenitor.

999 (I) Signaling received by T cells from DCs in splenocytes from the $Unc93b1^{+/+}$ and 1000 $Unc93b1^{R95L/R95L}$ mice.



1002

1003 Supplemental Figure 6. Gating strategies.

Representative gating strategies for germinal center B cells (GC B), age-associated B cells (ABC), marginal zone B cells (MZ B), and follicular B cells, plasma cells, CD4+ T cells, CD8+ T cells, NKT, DNT, Treg, Tfh, eTh, Th17, NK, pDCs, mDCs and monocytes in spleen or peripheral blood. These strategies used for data presented in Figure 4 and Supplemental Figure 5.